Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Bullboard Posts
Post by QuercusAlbaon May 04, 2006 8:07am
233 Views
Post# 10794065

FDA grants fast-track status...

FDA grants fast-track status... What do you know - two pieces of good news lately. Bear in mind that "fast" here is a relative term. Approval is years and many many dollars away. e-coli vaccine approval is the next big milestone. Good luck to all. QA Bioniche wins fast-track status for cancer drug 04/05/06 TORONTO (Reuters) - Bioniche Life Sciences said on Thursday the U.S. Food and Drug Administration has granted it fast track designation for its Urocidin bladder cancer treatment. Bioniche, which announced in February that the FDA approved its Phase 3 clinical trial with Urocidin, said the fast track designation means that when data from its Phase III program becomes available, it could expect an expedited review of a licensing application for Urocidin. "This designation gives us great confidence that Urocidin will be available to uro-oncologists for their refractory patients at the earliest possible opportunity," Bioniche Chief Executive Graeme McRae said in a release. Bioniche said patient enrollment for its Phase 3 program is expected to start by mid-2006.
Bullboard Posts